STAT+: Ban prior auth? And hospitals cut jobs
Reported by STAT News · all stories from statnews.com
Editorial digest
Banning prior authorizations and altering 340B drug program limits could result in hospitals reducing staff positions. This potential outcome suggests significant financial impacts on healthcare providers.
Digests are written in our own words from the publisher's headline — we never reproduce article text. Read the original for the full reporting.
Read the full story at STAT News →More like this
Other stories our editors tagged with the same themes.
- Trusted health newsroom10/26/2026
STAT+: HHS relaxes security, transparency rules for health record software used by hospitals
Federal health officials have eased transparency and data protection mandates for hospital electronic record platforms.
- Trusted health newsroom10/29/2026
STAT+: The EPIC investigation, and a Teladoc surprise
New reporting examines an inquiry into Epic alongside an unexpected update involving telehealth company Teladoc.
- Trusted health newsroom10/28/2026
STAT+: As Epic’s dominance grows, its iron grip is choking innovation in health technology
Epic Systems' expanding market influence is reportedly stifling technological innovation across the healthcare sector.
- Trusted health newsroom10/30/2026
STAT+: FDA, CMS scramble to avoid regulatory logjam as more states look to test AI in clinical settings
Federal health agencies are working quickly to prevent oversight bottlenecks as states prepare clinical artificial intelligence trials.
- Trusted health newsroom10/22/2026
STAT+: FDA finalizes its guidance on apps related to drugs, pharma rejoices
Federal regulators have completed formal guidelines for software applications paired with medications, drawing positive reactions from pharmaceutical manufacturers.
- Trusted health newsroom10/22/2026
STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction
Virtual clinics are providing off-label GLP-1 therapies for substance use disorders before receiving formal regulatory authorization.